Vaccine:降低低密度脂蛋白(LDL)的疫苗已在动物上初显成效

2015-11-11 Mechront 译 MedSci原创

研究人员表明,与他汀类药物相比,预防高胆固醇疫苗可能是更有效。该疫苗为PCSK9抑制剂,PCSK9是一种调节血液中胆固醇的数量的蛋白。2015年FDA批准Alirocumab和Evolocumab上市。这两种新型降脂药虽然效果优于他汀类,但是价格非常昂贵!虽然现在他汀类得到广泛使用,但是并不能对每一个人都有效。新墨西哥大学和美国国立卫生研究院的研究者在《Vaccine》上发表文章称,他们发明了一种

研究人员表明,与他汀类药物相比,预防高胆固醇疫苗可能更有效。该疫苗为PCSK9抑制剂,PCSK9是一种调节血液中胆固醇的数量的蛋白。

2015年FDA批准Alirocumab和Evolocumab上市。这两种新型降脂药虽然效果优于他汀类,但是价格非常昂贵!虽然现在他汀类得到广泛使用,但是并不能对每一个人都有效。

新墨西哥大学和美国国立卫生研究院的研究者在Vaccine上发表文章称,他们发明了一种疫苗,可以显著降低老鼠和猕猴的低密度脂蛋白 (LDL)。

脂蛋白是携带血液中胆固醇的分子,因为胆固醇不能溶解在血液里,就由脂蛋白带着胆固醇在体内穿梭,包括低密度脂蛋白(LDL)和高密度脂蛋白(HDL)。

LDL被认为对人体有害,因为它会导致胆固醇附着在动脉壁上。当体内胆固醇含量超出人体需求时,多余的胆固醇就会进入血液循环中,缓慢沉积在动脉壁上,最终导致动脉粥样硬化,增加心血管风险,尤其是冠心病。

HDL被认为对人体有益。因为它会收集血液循环中的LDLs和附着在动脉壁上的胆固醇,带它们去肝脏内分解掉。

当体内HDL水平升高后,LDL将会降低。专家称:HDL应该在60mg/dL。通过改变生活方式可以增加体内HDL水平,如戒烟、减肥、多运动、限酒、选择更健康的脂肪等。

CDC推荐成年人应定期检测血脂。≥20岁的人群可每5年检查一次,不过有高危因素的人群自然检测频率需要更勤一些。

原始出处:

Crossey E, Amar MJ,et al.A cholesterol-lowering VLP vaccine that targets PCSK9.Vaccine. 2015 Oct 26;33(43):5747-55.

Mouse Study Could Lead To Vaccine To Prevent High Cholesterol.

CDC:LDL and HDL: “Bad” and “Good” Cholesterol

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1773511, encodeId=cfaa1e735115e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Jan 25 11:06:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325137, encodeId=85a8132513e32, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422531, encodeId=034d1422531a9, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424648, encodeId=2d911424648fb, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43044, encodeId=cda0430449f, content=这都有疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Nov 12 11:30:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2016-01-25 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1773511, encodeId=cfaa1e735115e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Jan 25 11:06:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325137, encodeId=85a8132513e32, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422531, encodeId=034d1422531a9, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424648, encodeId=2d911424648fb, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43044, encodeId=cda0430449f, content=这都有疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Nov 12 11:30:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1773511, encodeId=cfaa1e735115e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Jan 25 11:06:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325137, encodeId=85a8132513e32, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422531, encodeId=034d1422531a9, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424648, encodeId=2d911424648fb, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43044, encodeId=cda0430449f, content=这都有疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Nov 12 11:30:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2015-11-13 zhwj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1773511, encodeId=cfaa1e735115e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Jan 25 11:06:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325137, encodeId=85a8132513e32, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422531, encodeId=034d1422531a9, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424648, encodeId=2d911424648fb, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43044, encodeId=cda0430449f, content=这都有疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Nov 12 11:30:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1773511, encodeId=cfaa1e735115e, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Mon Jan 25 11:06:00 CST 2016, time=2016-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325137, encodeId=85a8132513e32, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1422531, encodeId=034d1422531a9, content=<a href='/topic/show?id=58b810e5814' target=_blank style='color:#2F92EE;'>#LDL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10758, encryptionId=58b810e5814, topicName=LDL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=382c3719677, createdName=zhwj, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1424648, encodeId=2d911424648fb, content=<a href='/topic/show?id=5a3b8441438' target=_blank style='color:#2F92EE;'>#脂蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84414, encryptionId=5a3b8441438, topicName=脂蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=23ea3924919, createdName=juliusluan79, createdTime=Fri Nov 13 13:06:00 CST 2015, time=2015-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43044, encodeId=cda0430449f, content=这都有疫苗, beContent=null, objectType=article, channel=null, level=null, likeNumber=143, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Nov 12 11:30:00 CST 2015, time=2015-11-12, status=1, ipAttribution=)]
    2015-11-12 lixh1719

    这都有疫苗

    0

相关资讯

ARD:RA等位基因与患者低密度脂蛋白水平降低相关

低密度脂蛋白(low density lipoprotein ,LDL)胆固醇是冠状动脉疾病(coronary artery disease,CAD)的主要危险因素。虽然类风湿关节炎(RA)患者低密度脂蛋白的水平较正常人群低,但其冠状动脉疾病的患病率却更高。这可能是由于长期的慢性炎症所导致。遗传因素在RA的病程进展中发挥着重大作用,与患者的免疫功能失调以及炎症反应相关。这些相关的遗传因素可能也影响

J Hypertens:更佳血压和LDL水平对复发性卒中和认知障碍研究正在开展

以往有很多研究认为降低血压,以及降低LDL-C水平,可能能减少卒中的复发,以及减少认知障碍的发生。对于血压本身还存在争议,是否存在J型曲线一说。然而,血压与LDL-C相互作用,并不清楚。而且,最佳血压水平与LDL-C水平对卒中复发和认知障碍减少是否有更好的作用,这是值得研究的课题。一项全球多中心,随机对照,3x2析因设计的试验正在开展,试图解决这一难题。这项研究注册:NCT01563731。这

WCC 2014:总胆固醇和LDL-C水平升高可导致慢性肾病风险增加

世界心脏联合会主办的2014年世界心脏病学大会上公布的一项回顾性分析显示,总胆固醇和低密度脂蛋白胆固醇水平升高与冠心病患者的慢性肾病风险增加显著相关。 这项分析由加州大学旧金山分校的医学教授Prakash Deedwania医生及其同事进行,所分析的数据来自两项大型、随机、对照试验(TNT和IDEAL),共涉及超过19,000例接受阿托伐他汀或辛伐他汀治疗的冠心病患者,研究者在这些患者

Am J Cardiol:脂蛋白亚组分评估有助预测冠脉钙化

  美国学者的一项研究表明,在心血管中等风险的患者中,脂蛋白亚组分评估可为预测冠脉钙化提供传统危险因素之外的附加信息。论文于2012年11月7日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   此项研究共序贯性纳入410心血管中等风险患者。受试者平均年龄57岁,女性占29%,并且均接受冠脉钙化(钙化评分)CT评估。利用经验证的超速离心法对洗脱脂蛋白亚组分(低、

心脏病疫苗和单克隆抗体有望出现

  心血管前沿生物学会议(FCVB)2012年会的一项报告指出,抗动脉粥样硬化的疫苗和单克隆抗体将很快改变心脏病治疗现状。由于其以心血管疾病(CVD)的潜在病因为靶向,因此可被视为真正的开创性方法。   CVD的现有治疗几乎均以改变危险因素为关注点,但仅能使患者的CVD风险降低40%。早在1990年代即已确认了抗动脉斑块内氧化低密度脂蛋白(LDL)的抗体。瑞典隆德大学Nilsson教授领导的团队